8-K - Coeptis Therapeutics Holdings, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Coeptis Therapeutics Holdings, Inc. implemented an option repricing/exchange program for officers and directors, converting certain out-of-the-money options to restricted stock and accelerating the vesting of all options. The company also regained compliance with Nasdaq listing rules after previously failing to hold a required annual meeting.

Key Takeaways

1The company implemented an option repricing/exchange program on February 11, 2026, approved by the Board of Directors and stockholders.

2Option holders could elect to either reprice options with exercise prices above current fair market value or surrender them for restricted stock.

3All options, including those with exercise prices above current fair market value, were accelerated to become fully vested.

4Nine officers and directors surrendered options for restricted stock, with David Mehalick exchanging the largest amount (51,250 shares).

5The same nine individuals also exercised retained options, with David Mehalick exercising options for 148,875 shares of restricted common stock.

6The company regained compliance with Nasdaq Listing Rules on February 9, 2026, after previously failing to hold an annual meeting within twelve months of December 31, 2024.

Current Report Details

Event Type

Management Change

Other Event

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 1

Management Change

8.01

Other Events As previously reported by Coeptis Therapeutics Holdings, Inc. (the “Company”), it had received a written notice from The Nasdaq Stock Market (“Nasd

Other Event

Executive & Director Changes

David Mehalick

officer/director

surrendered options for restricted stock and exercised retained options

Effective: 2026-02-11